Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices

Aniek Dane (), Anne-Sophie Klein Gebbink, Jan-Dietert Brugma, Albane Degrassat-Théas, Martin J. Hug, Morten B. Houlind, P. Paubel, P. Hugo M. Kuy and Carin A. Uyl- de Groot
Additional contact information
Aniek Dane: Erasmus MC
Anne-Sophie Klein Gebbink: Erasmus MC
Jan-Dietert Brugma: Erasmus MC
Albane Degrassat-Théas: Assistance Publique-Hôpitaux de Paris (AP-HP)
Martin J. Hug: Freiburg University Medical Center
Morten B. Houlind: Copenhagen University Hospital, Amager and Hvidovre
P. Paubel: Assistance Publique-Hôpitaux de Paris (AP-HP)
P. Hugo M. Kuy: Erasmus MC
Carin A. Uyl- de Groot: Erasmus University Rotterdam

Applied Health Economics and Health Policy, 2023, vol. 21, issue 6, No 7, 905-914

Abstract: Abstract Background Increasing pharmaceutical expenditure challenges the sustainability and accessibility of healthcare systems across Europe. Confidentiality restraints hinder assessment of actual prices of Orphan Medicinal Products (OMPs). Hence, we assessed the real prices of brand-name OMPs around market exclusivity expiry (MEE). Objective We aimed to explore developments in published list prices (LPs) and confidential hospital purchase prices (PPs) of brand-name OMPs relative to their market exclusivity status in Western European countries with similar GDPs. Methods We analyzed LPs and PPs of 13 selected OMPs purchased by university hospitals in Western European countries between 2000 and 2020. For confidentially reasons, proportions were used, with the Dutch LPs of the selected OMPs at the year of MEE serving as reference values. PPs included pre-purchase discounts. Rebates were not considered. Results Data were analyzed from hospitals in Denmark (DK) (n = 1), France (FR) (n = 1), Germany (DE) (n = 2), and the Netherlands (NL) (n = 1). Average LPs and PPs of included OMPs dropped gradually but limited over time, with no explicit price drop after MEE. LP levels differed more per country than PP levels: LP range before MEE was 164% (DE)–101% (FR) and after MEE was 135% (DE)–82% (FR); PP range before MEE was 150% (DE)–102% (FR) and after MEE was 107% (DE)–80% (FR). Overall differences between LPs and PPs were

Date: 2023
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40258-023-00832-6 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:aphecp:v:21:y:2023:i:6:d:10.1007_s40258-023-00832-6

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40258

DOI: 10.1007/s40258-023-00832-6

Access Statistics for this article

Applied Health Economics and Health Policy is currently edited by Timothy Wrightson

More articles in Applied Health Economics and Health Policy from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().